Abstract 1802
Background
Targeting programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has failed to provide durable clinical benefit for a majority of patients with solid carcinomas. Recent preclinical and clinical data suggests that addition of the IL-15 superagonist N-803 improves response rates to anti-PD-1 or anti-PD-L1 therapy. Thus, we hypothesized that N-809, a novel bifunctional agent comprised of N-803 fused to two single chain anti-PD-L1 variable region domains, would promote potent anti-tumor efficacy and immune activation in murine models of solid carcinomas.
Methods
The functionality of the N-809 components was examined in vitro. Anti-tumor efficacy of N-809 versus a clinically relevant dose of N-803 + anti-PD-L1 was assessed using murine MC38 colon and 4T1 triple negative breast tumor models. The immune-mediated mechanism of N-809 was examined in spleen and tumor using comprehensive flow-based analyses and functional assays. Serum cytokine levels were also measured. Finally, effects on tumor gene expression were examined using Nanostring. Nant biosciences provided N-809 as per Cooperative Research and Development Agreement with NCI.
Results
In vitrostudies confirmed that both components of N-809 were functional. N-809 drastically reduced MC38 tumor burden leading to increased survival and significantly reduced spontaneous lung metastasis of 4T1 tumors. In both tumor models, N-809 had improved efficacy versus a clinically relevant dose of N-803 + anti-PD-L1. In the MC38 model, N-809 increased serum levels of IFNg, TNFa, and IL-10. Depletion studies revealed that CD8+T and NK cells are required for the anti-tumor efficacy of N-809. The immune analysis showed enhanced CD8+ T and NK cell tumor infiltration, activation, and function. To determine the mechanism of the increased CD8 and NK cell infiltration, analyses were performed to examine tumor chemokines and inhibition of immune cell migration. Gene analysis revealed changes in chemokines, chemokine receptors, and immune response genes.
Conclusions
N-809 has anti-tumor efficacy in two murine carcinoma model mediated by increasing the number, activation, and function of CD8+ T cells and NK cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Funding
Nant Bioscience.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract